SYRS News and Press, Syros Pharmaceuticals Inc. From 04/30/20

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 7, 2020 to report its first quarter 2020 financial results and provide a co...

Introduction Syros ( SYRS ) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RARα ago...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 5, 2020 to report its fourth quarter and full year 2019 financial results...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences: Cowen and Company 40 th Annual Health Care Conference in Boston, MA on Monday, March 2, ...

Nearly 1.8 million Americans were diagnosed with cancer last year. Around the world, the total was close to 17 million. It's not surprising, then, that more than 700 biopharmaceutical companies have experimental cancer drugs in late-stage development. Beta-thalassemia, on the other hand, is a...

Initial Tranche Extends Cash Runway into 2022, Beyond Planned Clinical Data Readouts for Two Lead Programs Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of a $60 million senior secured loa...

Syros Pharmaceuticals (NASDAQ: SYRS) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, Syros announced new preclinical data showcasing the differentiating therapeutic effects of its CDK7 vs CDK12/13 inhibitors. More br...

Differences in CDK7 and CDK12 Biology Point to Distinct Therapeutic Strategies Additional Presentations Highlight Power of Syros’ Gene Control Platform to Identify New Drug Targets Across a Range of Cancers Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development o...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the Phase 1 clinical trial of SY-5609, its highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor....

Syros Pharmaceuticals ( SYRS ) is a small cap, clinical stage pharmaceutical company. As such it carries all the risks and potentials to the category. Mainly, if its drugs fail to gain regulatory approval, it will turn out to be a bad investment. If one or more drugs gain regulatory approval, ...